Q4 2023 · —
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$7.61M-$7.61M derivedno prior Q4 2022 on fileN/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$5,511,844—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q4 2022 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR